Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois.

Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation.

Title: Driving to a New Standard of Care in Lung Nodule Management: Preliminary Results from the Nodify Lung Real-World CLARIFY Study
Presenter: Michael Kammer, PhD, Head of Radiomics at Biodesix
Location: Learning Theater 4
Date and Time: Biodesix Learning Theatre, October 21 at 2:00 pm CDT
Description: This presentation will review analysis from the first 1,000 patients enrolled in the CLARIFY study. The CLARIFY study began patient enrollment shortly after the 2024 CHEST Annual Meeting and is designed to confirm performance of the Nodify CDT® and Nodify XL2® tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients with at least 1-year follow-up since being tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of the Nodify Lung tests.

A national analysis of lung nodules receiving clinical work-up across diverse care settings will also be presented at the meeting, highlighting the need for more structured lung nodule management approaches to optimize efficiency of healthcare resource utilization and improve patient outcomes.

Title: Pulmonary Nodule-related Healthcare Resource Utilization After Diagnosis of Pulmonary Nodule in the United States
Presenting Author: Kimberly Le, PharmD, MS, MBA, Director of Health Economics Outcomes Research at Biodesix
Date and Time: Wednesday, October 22, 10:20 AM

It is important to note that there will be numerous independent presentations by healthcare professionals highlighting the clinical value of the Nodify Lung tests in their own real-world patient populations. Examples are below.

Title: Comparison of the Blood-based Nodify XL2 Test with PET/CT to Evaluate for Malignancy in Indeterminate Pulmonary Nodules in an Endemic Fungal Region
Presenting Author: Michael Torres Lizardi, MD
Date and Time: Sunday, October 19, 11:20 AM CDT

Title: Impact of the Nodify Lung Test Strategy in the Risk Stratification of Lung Nodules in Patients of a Pulmonary Practice in Miami
Presenting Author: Elizabeth Samper Perez
Date and Time: Wednesday, October 22, 10:20 AM CDT

Title: The Association of Lung Cancer Screening (LCS) and Proteomic Lung Nodule Testing in an Unrepresentative Minority Community (UMC) in Brooklyn, NY
Presenting Author: Juan Martinez Zegarra, MD
Date and Time: Wednesday, October 22, 10:20 AM CDT

Title: A Retrospective Analysis of Biodesix Biomarker to Assess Efficacy in Risk Stratification and Reduction of Invasive Surgical Procedures in Detected Solitary Pulmonary Nodules
Presenting Author: Kevin Huynh, DO
Date and Time: Wednesday, October 22, 10:20 AM CDT

In addition, Biodesix executive leaders and medical officers will be present at the Biodesix booth #1012 to discuss the future of biomarkers for lung nodule management and lung health diagnostics.

“It is an exciting time to be part of the lung diagnostics space, with biomarkers poised to transform and improve patient care,” said Scott Hutton, CEO at Biodesix. "With thousands of lung specialists coming together, the CHEST Annual Meeting offers a pivotal moment in lung diagnostics and in the fight against lung cancer. It’s great timing with Lung Cancer Awareness Month starting November 1st.”

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.22
+1.41 (0.78%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.